SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (7805)3/31/2000 7:41:00 AM
From: jayhawk969  Read Replies (1) of 9719
 
David

Sepracor including the over-allotment raised $460 million in convertible debt.

Bio Transplant raised $9.7 MM in a private Placement.

NPS Pharmaceuticals, Inc.
private placement of 3,900,000 shares The purchase price per share is $12.00. Upon closing the transaction, the Company will
have approximately 23.6 million shares outstanding and $75 million in cash. Proceeds from this private placement are estimated at $43.5 million.

Neuocrine Bioscience
2,327,777shares $28.50/share $66,341,645 capital raised

J.D.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News